x
ServiziMenu principaleHome

Fondazione Monza Brianza Bambino Mamma

Person responsible for CTC programme: Professor Andrea Biondi and Dr.Valentino Conter

Hospital overview
The “Fondazione Monza Brianza Bambino Mamma (FMBBM)” is public-private Foundation located at the San Gerardo Hospital, in Monza, the teaching Hospital of the University of Milano-Bicocca (Unimib) with all specializations for medicine and surgery.

The clinical and research activities in the field of hemato-oncology are located in the “Centro M.L. Verga”, a new four-floor building covering a total of 7300 sq, with 15 beds for inpatient and 10 for Stem Cell Transplantation (including two rooms for gene-therapy), and 1300 of diagnostic and research activities of the Fondazione Tettamanti (Centro Ricerca Tettamanti). It is a leading center in Italy (one the largest for accrual of leukemia and lymphoma patients up to the age of 18 years), coordinating several national and international clinical protocols for newly diagnosed patients. Since 2010 a program for phase I/II studies of new drugs Is active with a clinical trial unit and a center for biostatistics and data analyses. The center is active member of the ITCC and the only Italian center accredited as coordinator of European ITCC clinical studies.

The Centro Ricerca Tettamanti operates in the field of research on childhood leukemia and blood disorders. The Verri Laboratory is a GMP facility accredited by the AIFA ( since 2007) for production of cell and non-viral gene therapy products for clinical use. The research team brings together complementary skills and expertise required to address the proposed project, comprising long experience in cell-based clinical trials in the field of immunotherapy. The Research Centre has the complete equipment for cellular and molecular biology, sequencing, cytometry and for in vivo experiments.

Tax

Please note that doctors taking part in a CTC in Italy will be subject to paying Italian tax

CTC programmes offered

1. Pediatric Hematology-Oncology

Discipline:

Pediatric Oncology

Programme mentor:

Dr.Carmelo Rizzari and Prof. Andrea Biondi

Duration: 3 - 6 months
Type: Visiting Observership  
Language requirements:

Good knowledge of English required. Basic Italian encouraged.

Programme description:
  1. Diagnostic work-up for pediatric patients (up to 18 yrs) with diagnosis of acute and chronic leukemia, MDS, histiocytosis and lymphoma ( HD and NHL);
  2. Management of front-line clinical protocols for diagnosis and treatment and the most frequently occurring complications during treatment;
  3. Patient follow-up in the outpatient clinic;
  4. Management of pain;
  5. Management of patient off-therapy.

2. Pediatric Stem Cell Transplantation and Cell&Gene Therapy

Discipline:

Hemopoietic Stem Cell Transplantation

Programme mentor: 

Dr.Attilio Rovelli and Prof.Adriana Balduzzi

Duration: 3 - 6 months
Type: Visiting Observership  
Language requirements: Good knowledge of English required. Basic Italian encouraged
Programme description:
  1. Diagnostic work-up of patients eligible for Hemopietic Stem Cell Transplantation HSCT form related or unrelated, and aploidentical donors for leukemia, lymphoma, metabolic and genetic diseases;
  2. Management of HSCT procedure during conditioning, SC collection and post-transplant including GVHD and infectious complications ;
  3. Cell manipulation of the graft including CD34 positive selection and alfa-beta-depleted aploidentical SC source;
  4. Patient follow-up in the outpatient clinic and in the log-term follow-up;
  5. Cell and gene therapy including use of MSC and CAR-T cells.

3. Gene and Immune Lab.

Discipline:

Hematology & Immunology

Programme mentor: 

Dr.Giovanni Cazzaniga- Prof. Andrea Biondi

Duration:  3 - 6 months
Type: Visiting Observership
Language requirements:

Good knowledge of English required. Basic Italian encouraged.

Programme description:
  1. Advanced diagnostic work up acute and chronic leukemia, MDS, histiocytosis and lymphoma ( HD and NHL), including multiparametric FCM, molecular cytogenetics and NGS approaches;
  2. Evaluation of MRD by Ig/TCR clonotypic approach by using standard and NGS approaches;
  3. Exome and whole genome for diagnostic genetics of acute leukemia;
  4. In vitro and in vivo modelling of childhood leukemia, including “niche” for ALL and AML;
  5. CART development and in vitro and in vivo activity assessment .

Follow us